Whitefish, Mont. – September 25, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.
Company secures third straight Inc. 5000 ranking as growth trajectory accelerates
STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.
CEO cites sustained demand for science-backed longevity products
"Being recognized on the Inc. 5000 for a third consecutive year is especially meaningful because it demonstrates sustained growth rather than a single exceptional year," said Dave Huffman, CEO of STEMREGEN. He attributed the growth to rising awareness of stem cells' role in the body's natural repair system and expanding demand for science-based healthy-aging solutions.
Product line targets endogenous stem cell mobilization and circulation
STEMREGEN's plant-based supplements are built on more than two decades of research by stem cell scientist Christian Drapeau, MSc. The formulations target the release of stem cells from bone marrow, their circulation through the bloodstream, and their migration into tissues.
The company's expansion tracks broader consumer, clinical, and athletic interest in regenerative health and longevity. Full 2026 Inc. 5000 results, including sortable company profiles by industry and location, are published on Inc.com.